Park Ha Biological Technology is trading 14.23% down at $2.05, with broader biotech weakness as context; no clear company-specific catalyst was identified. - Available news and filing listings show no new catalyst for the October 7 session, and no clear company-specific announcement or October 7 filing was identified. - XBI was down 2.50% during the regular session and closed down 3.39% on October 6; this supports sector weakness as context, not a confirmed company-specific cause.